Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $120.00 short put and a strike $110.00 long put offers a potential 17.23% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $120.00 by expiration. The full premium credit of $1.47 would be kept by the premium seller. The risk of $8.53 would be incurred if the stock dropped below the $110.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Lilly board hikes dividend by 15%
Mon, 16 Dec 2019 21:57:00 +0000
Eli Lilly & Co. said late Monday that its board approved a 15% hike to the company's quarterly dividend. Lilly said it will pay a dividend of 74 cents a share, up from 64.5 cents a share, on March 10, 2020 to shareholders of record as of Feb. 14. Lilly shares were flat after hours, following a 1.1% increase to close the regular session at $122.85.
Lilly Announces 15 Percent Dividend Increase
Mon, 16 Dec 2019 21:25:00 +0000
The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter of 2020 will be $0.74 per share on outstanding common stock. This raises the annual indicated rate to $2.96 per share.
Lilly's Cyramza Gets CHMP Recommendation for First-Line NSCLC
Mon, 16 Dec 2019 13:05:01 +0000
Lilly's (LLY) regulatory application seeking approval for cancer drug, Cyramza, in combination with erlotinib for treating EGFR-mutated NSCLC in first-line setting gets positive CHMP opinion for approval in EU.
Lilly to Integrate Dexcom CGM into Personalized Diabetes Management System
Mon, 16 Dec 2019 11:45:00 +0000
Eli Lilly and Company (NYSE: LLY) has announced a global commercialization agreement to integrate DexCom, Inc. (NASDAQ: DXCM) products into Lilly's personalized diabetes management system, currently in development to advance the treatment of diabetes. Under the terms of the non-exclusive agreement, Lilly will use Dexcom's continuous glucose monitoring (CGM) devices in both the pen- and pump-based platforms of the system being designed to help improve diabetes management.
Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study
Fri, 13 Dec 2019 13:01:01 +0000
This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion
Also on Market Tamer…
Follow Us on Facebook